I'm LongbridgeAI, I can summarize articles.Fortress Biotech reported a Q2 FY26 net loss of $2.5 million, reversing from a $13.4 million profit in the prior year. Revenue increased 14% to $18.7 million, driven by $17.8 million from marketed dermatology products. R&D and SG&A expenses decreased significantly. Cash reserves rose to $196.6 million. Management highlighted momentum in partnered programs, including Crystalys’ Series B funding.
- Fortress Biotech Q2 2026 revenue rose 14% to $18.7 million versus Q2 2025, with $17.8 million from marketed dermatology products. * Net loss attributable to common stockholders turned to $2.5 million, or $0.08 per share, from net income of $13.4 million a year earlier. * R&D expense fell to $0.8 million from $8.1 million, while SG&A dropped to $20.8 million from $38.8 million. * Cash and cash equivalents climbed to $196.6 million at June 30 from $79.4 million at Dec. 31, 2025. * Management cited momentum across partnered programs, including Crystalys’ $130 million Series B for dotinurad and royalties from ZYCUBO and UNLOXCYT launches. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here